Who We Are
Apex Healthcare Sdn Bhd, a wholly owned subsidiary of Pharmora Investment Holdings Pte Ltd, is a leading pharmaceutical group headquartered in Singapore, with operating subsidiaries in Malaysia and Singapore, and a commercial presence in over 20 countries worldwide.
Founded in 1962 as a retail pharmacy in Melaka, our core expertise today is in the development, manufacturing, sales and marketing, distribution and wholesaling of pharmaceuticals, consumer healthcare products and medical devices.
Our Business
Through manufacturing and distribution, we make quality pharmaceuticals, consumer healthcare products and medical devices available to our valued customers through our comprehensive supply channels.
Since our establishment in 1962, our business has been focused on making pharmaceuticals, consumer healthcare products and medical devices available to customers in the markets in which we operate, through manufacturing and distribution, and in a manner which fairly rewards all stakeholders. We know our business intimately and have a growing network of loyal customers; this will remain our business for the future. Our confidence in our business stems from a conscious decision to focus resources on our area of expertise, which enables us to increase our capabilities, efficiencies and understanding of underlying trends in the industry.
Our Mission
Restoring Health, Enhancing Life.
Apex’s mission is to bring better health and quality of life to all through its businesses. Healthcare professionals use our medicines and medical devices to treat and manage respiratory, dermatological, cardiovascular, gastrointestinal conditions and more. Consumers use our range of consumer healthcare products to enhance their wellbeing. We take heart in knowing that our products play a role in the restoration of health and enhancement of life in those who use and trust them.
Our Core Tenets
Service, Quality and Integrity, Always.
Service is an integral tenet of Apex. From the very first customer in 1962, Apex has striven to provide an efficient, professional and responsive touch in our dealings with suppliers, healthcare professionals, customers and all whom we come across.
The quest to improve Quality is a never-ending journey. We will continually refine our processes and systems in order to secure all commercially relevant global quality certifications.
Integrity is an inescapable part of our business and runs through our value chain from research and development, manufacturing, warehousing, sales and marketing till final delivery. We value honesty in our dealings and there is no compromise.
- Kee Tah Peng established the first Apex Pharmacy in Jalan Munshi Abdullah, Melaka.
- Generic pharmaceutical manufacturing established in Singapore.
- Generic pharmaceutical manufacturing relocated to Ayer Keroh Industrial Estate, Melaka as Xepa-Soul Pattinson.
- Xepa-Soul Pattinson relocated to its new plant in Cheng Industrial Estate, Melaka.
- Apex Healthcare Berhad listed on KLSE Second Board on 26 June 2000.
- ISO 9001:2008 certification for Xepa-Soul Pattinson (Malaysia) Sdn Bhd.
- Apex Healthcare Berhad transferred to KLSE Main Board on 15 August 2003.
- Ground Breaking Ceremony for the new Apex Pharma Centre in Subang Jaya on 21 October 2003.
- Soft Opening of Apex Pharma Centre.
- Acquisition of 25% equity interest in pharmaceutical group Xiamen Maidiken Science & Technology Co., Ltd. China.
- Acquisition of Singapore pharmaceutical distributor Grafton Pharmasia Pte Ltd, now renamed Apex Pharma Marketing Pte Ltd.
- Official Opening of Xepa-Soul Pattinson’s new Liquids Pharmaceutical Plant.
- Equity interest increased to 32.4% in Xiamen Maidiken Science & Technology Co., Ltd. China.
- Officlal opening of Apex Pharma Centre, housing head office and specialised pharmaceutical warehouse facilities.
- Retirement of the founder, Kee Tah Peng, as Group Chairman.
- ISO 9001:2008 certification for Apex Pharmacy Marketing Sdn Bhd.
- Opening of retail pharmacy outlet in City Square, Johor Bahru.
- Divestment of investment in Xiamen Maidiken Science & Technology Co., Ltd. China.
- Signing of Memorandum of Understanding for ABio Orthopaedics Sdn Bhd.
- Opening of the new Singapore premise at Loyang Way 1.
- Launch of Apex Healthcare CPD (Continuing Professional Development).
- ISO 13485:2003 certification for Xepa-Soul Pattinson (Malaysia) Sdn Bhd.
- Commencement of construction of SPP NOVO, a new Oral Solid Dosage manufacturing plant.
- EU GMP certification for Xepa-Soul Pattinson (Malaysia) Sdn Bhd.
- EN ISO 13485:2016 accreditation for the Design and Development, Manufacture and Distribution of Sterile Eye Drops, certifying compliance with EU standards for Xepa-Soul Pattinson (Malaysia) Sdn Bhd.
- GMP clearance from the Australian Therapeutic Goods Administration (TGA) for Non-Sterile Finished Product for Xepa-Soul Pattinson (Malaysia) Sdn Bhd.
- Renewal of EU GMP certification for Xepa-Soul Pattinson (Malaysia) Sdn Bhd, the original of which was secured in 2017.
- Xepa-Soul Pattinson (Malaysia) Sdn Bhd exported its contract-manufactured Eye Mo eye drops to Mexico for the first time, marking its entry into Latin America.
- Xepa-Soul Pattinson (Malaysia) Sdn Bhd obtained Halal certification for its products.
- Completion of the delisting of Apex Healthcare Berhad from Bursa Malaysia.
- Privatization resulting in the transition of Apex Healthcare Berhad into Apex Healthcare Sdn Bhd
Corporate Structure
[th-slider design=”design-2″ arrows=”true” autoplay=”false” dots=”false” loop=”true” slidestoshow=”6″ extra_class=”milestones”]
Our Accolades
The Edge Billion Ringgit Club Award
We are proud to have won The Edge Billion Ringgit Club (BRC) award three times since 2019. Our achievements include recognition for delivering the Highest Return to Shareholders in 2019 in the healthcare sector, followed by successive wins in 2024 and 2025 for Highest Return on Equity in the healthcare sector.
MOPI Pharma Industry Awards 2024
At the inaugural MOPI Pharma Industry Awards 2024 held in conjunction with the Regulatory Plus Conference 2024, Xepa-Soul Pattinson (Malaysia) Sdn Bhd (‘Xepa’), a wholly owned subsidiary of Apex Healthcare Sdn Bhd was conferred the winner of the ‘Fastest Growing Export Revenue (2019 to 2023)’ in the category for companies with export revenue exceeding RM 50 million. This achievement is a testament to the dedication of our people and highlights our commitment to expanding Malaysia’s footprint in the global market while providing quality and affordable medicines.
Xepa was also the runner-up for the ‘Most Productive Company 2023 (Revenue per Employee)’ under the Pharma category.
